// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Comparative efficacy on mucosal healing of pharmacological therapies for moderate-to-severe ulcerative colitis, based on prior exposure to tumour necrosis factor antagonists: A systematic review and network meta-analysis

P Paschos - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapy

H Gordon - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Entyvio

Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52

D Garca-Olmo - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

CX601

Should extraintestinal manifestations (EIMs) be part of disease activity assessment in ulcerative colitis?

A Walsh - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

The impact of a virtual clinic on clinical decision-making and healthcare resource use vs. standard care: The Oxford experience

M FitzPatrick - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Infliximab

Does radiation to the pelvis portend worse ileal pouch outcomes? An international multi-institution collaborative study

A Lightner - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

A pilot study: A psychological support service for patients with inflammatory bowel disease (PSSPIBD)

R McGeer - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Efficacy of vedolizumab for induction and maintenance of clinical remission in ulcerative colitis: The UCLH experience

M Vinayaga-Pavan - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Patient-reported outcomes in pain and discharge correlate with objective assessments of perianal fistula remission in Crohn’s disease (CD)

J Pans - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Designing the first pan-European paediatric IBD database to allow the study of incidence and prevalence of UC, CD, and their rare and severe complications

P Kemos - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

A specialised inflammatory bowel disease service provides equality of access to healthcare, irrespective of deprivation indices

D Sawbridge - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Natural disease course of inflammatory bowel disease unclassified in a prospective European population-based inception cohort—the Epi-IBD cohort

J Burisch - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Smoking in UC is associated with decreased thiopurine use but not steroid dependency or colectomy

J Blackwell - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Incidence of paediatric stricturing duodenal Crohn’s disease in South-East Scotland: A 12-year population-based cohort study

C Burgess - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Natural history of Paediatric Black British inflammatory bowel disease

A -M Grima - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

The interleukin-6 receptor as a target for prevention of Crohn’s disease and ulcerative colitis; a Mendelian randomisation study

C A Parisinos - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

ILS-969

Prevalence and phenotype of inflammatory bowel disease across primary and secondary care: Implications for colorectal cancer surveillance

N Heerasing - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Centre volume bias for restorative surgery after ulcerative colitis colectomy in England and Sweden

G Worley - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

The psychosocial effects of inflammatory bowel disease on patients’ reproductive health—a systematic literature review

S Purewal - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Genetics, methylation, and disease state interact at the VMP1/MIR21 locus

K O'Leary - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved